Dabogratinib (TYRA-300) 80mg

Drug identity checked against registry records

Also recorded as TYRA-300

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaNCT07265947TYRAPhase 2Recruiting2030-10Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.